Stocks Health care ATNM
NYSE · Health careActinium Pharmaceuticals, Inc. (ATNM)
In fiscal 2025 capital spending exceeded operating cash flow by $24.7M. At June 30, 2026 it held $36.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.
Key facts about Actinium Pharmaceuticals, Inc.
- Net worth
- Actinium Pharmaceuticals, Inc. has a market value (market cap) of $49.7M at the latest share price, and shareholders' equity of $30.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $90K (+11.1% year on year), with a net loss of $33.9M.
- Cash flow
- In fiscal 2025 operations used $24.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 7, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Actinium Pharmaceuticals, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Actinium Pharmaceuticals, Inc. does
Actinium Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker ATNM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $90K | -$33.9M | -$1.09 | -$24.7M |
| 2024 | n/a | -$38.2M | -$1.27 | -$33.1M |
| 2023 | $81K | -$48.8M | -$1.83 | -$47.5M |
| 2022 | $1M | -$33M | -$1.37 | $8.3M |
| 2021 | $1.1M | -$24.8M | -$1.20 | -$21M |
| 2020 | n/a | -$22.2M | -$1.83 | -$21.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ATNM ranks in Health care
Latest SEC filings
What Actinium Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026
- August 7, 2026
- June 18, 2026Other event 8-K
- May 29, 2026
- May 8, 2026
- March 30, 2026
- March 26, 2026Shareholder vote results 8-K/A
- February 13, 2026
- November 26, 2025
- November 14, 2025Quarterly report 10-Q · period to September 30, 2025Revenue was $90K; diluted EPS -$0.16 versus -$0.37.
Insider trades
What the people running Actinium Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 7 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 2, 2026 | Chell Jeffrey W.Director | Received as pay | 61,600 | - |
| September 2, 2026 | Steinhart Richard IDirector | Received as pay | 62,800 | - |
| September 2, 2026 | Seth SandeshChief Executive Officer, Director | Received as pay | 753,600 | - |
| September 2, 2026 | Seth SandeshChief Executive Officer, Director | Received as pay | 1,027,274 | - |
| September 2, 2026 | Almenoff June SherieDirector | Received as pay | 18,000 | - |
| September 2, 2026 | Shetty AjitDirector | Received as pay | 61,600 | - |
| September 2, 2026 | Nicholson, C. DavidDirector | Received as pay | 62,800 | - |
Who owns ATNM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
6 insiders reported holding 2,233,728 shares in total, about $3.5M at the last price.
| Holder | Shares |
|---|---|
| Seth SandeshChief Executive Officer, Director | 1,965,355 |
| Nicholson, C. DavidDirector | 63,300 |
| Steinhart Richard IDirector | 63,116 |
| Shetty AjitDirector | 62,357 |
| Chell Jeffrey W.Director | 61,600 |
| Almenoff June SherieDirector | 18,000 |
Questions about ATNM
What does Actinium Pharmaceuticals, Inc. do?
Actinium Pharmaceuticals, Inc. is a company in the Health care sector, listed on NYSE as ATNM. Its shares trade on NYSE under the ticker ATNM.
What is Actinium Pharmaceuticals, Inc.'s net worth?
Actinium Pharmaceuticals, Inc. has a market value (market cap) of $49.7M at the latest share price, and shareholders' equity of $30.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Actinium Pharmaceuticals, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $11.3M.
When did Actinium Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the new insider holdings from September 10, 2026.
When is Actinium Pharmaceuticals, Inc.'s next earnings report?
Actinium Pharmaceuticals, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ATNM with
Follow ATNM
Get an email when Actinium Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Actinium Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.